Transcode Therapeutics, Inc. SEC filings RNAZ
Transcode Therapeutics, Inc. has 324 filings in SEC EDGAR's recent list, going back to Dec 18, 2020. Its latest annual report, Form ARS, was filed on Jun 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 19, 2026 | — |
| EFFECT | Filing | May 19, 2026 | — |
| CORRESP | Letter to the SEC | May 15, 2026 | — |
| CORRESP | Letter to the SEC | May 15, 2026 | — |
| UPLOAD | Letter from the SEC | May 6, 2026 | — |
| UPLOAD | Letter from the SEC | May 6, 2026 | — |
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Dec 22, 2025 | — |
| CORRESP | Letter to the SEC | Dec 18, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Dec 17, 2024 | — |
| CORRESP | Letter to the SEC | Dec 13, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2024 | — |
| D | Filing | Dec 12, 2024 | — |
| DEFR14A | Filing | May 20, 2024 | — |
| EFFECT | Filing | Jan 18, 2024 | — |
| CORRESP | Letter to the SEC | Jan 17, 2024 | — |
| CORRESP | Letter to the SEC | Jan 17, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 16, 2024 | — |
| EFFECT | Filing | Sep 25, 2023 | — |
| CORRESP | Letter to the SEC | Sep 25, 2023 | — |
| CORRESP | Letter to the SEC | Sep 25, 2023 | — |
| CORRESP | Letter to the SEC | Sep 25, 2023 | — |
| CORRESP | Letter to the SEC | Sep 25, 2023 | — |
| CORRESP | Letter to the SEC | Sep 22, 2023 | — |
| CORRESP | Letter to the SEC | Sep 22, 2023 | — |
| CORRESP | Letter to the SEC | Sep 22, 2023 | — |
| CORRESP | Letter to the SEC | Sep 15, 2023 | — |
| CORRESP | Letter to the SEC | Sep 15, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 31, 2023 | — |
| EFFECT | Filing | Jun 6, 2023 | — |
| CORRESP | Letter to the SEC | Jun 6, 2023 | — |
| CORRESP | Letter to the SEC | Jun 5, 2023 | — |
| UPLOAD | Letter from the SEC | May 25, 2023 | — |
| RW | Filing | Feb 14, 2023 | — |
| EFFECT | Filing | Dec 16, 2022 | — |
| CORRESP | Letter to the SEC | Dec 14, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2022 | — |
| RW | Corresp | Dec 6, 2022 | — |
| DRS | Filing | Jul 29, 2022 | — |
| SEC STAFF LETTER | Filing | Jul 8, 2021 | — |
| EFFECT | Filing | Jul 8, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| CORRESP | Letter to the SEC | Jun 1, 2021 | — |
| CORRESP | Letter to the SEC | May 14, 2021 | — |
| CORRESP | Letter to the SEC | May 6, 2021 | — |
| CORRESP | Letter to the SEC | May 6, 2021 | — |
| CERT | 8a cert | Apr 27, 2021 | — |
| 8-A12B | Filing | Apr 26, 2021 | — |
| CORRESP | Letter to the SEC | Apr 23, 2021 | — |
| CORRESP | Letter to the SEC | Apr 23, 2021 | — |
| CORRESP | Letter to the SEC | Apr 16, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 14, 2021 | — |
| CORRESP | Letter to the SEC | Mar 11, 2021 | — |
| SEC STAFF LETTER | Filing | Jan 28, 2021 | — |
| DRSLTR | Filing | Jan 27, 2021 | — |
| DRS/A | Filing | Jan 27, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2021 | — |
| DRS | Filing | Dec 18, 2020 | — |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNAZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1829635
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.